A new study found that shingles vaccination was associated with slower epigenetic aging, lower inflammation, slower transcriptomic aging, and a lower composite biological aging score — with effects lasting more than four years. The mechanism is more interesting than the headline.
Most people think of the shingles vaccine as protection against a painful rash. That framing undersells it dramatically. A 2025 study published in *GeroScience* has reframed how longevity researchers should think about vaccination: not just as infection prevention, but as a biological age intervention with measurable effects on multiple aging clocks.
The findings are striking enough to deserve serious attention from anyone building a longevity protocol.
Kim and Crimmins (2025) analyzed data from the US Health and Retirement Study, a nationally representative longitudinal cohort of Americans over 50 that has been running since 1992. Their analysis covered 3,884 adults aged 70 and over, comparing those who had received the shingles vaccine against matched unvaccinated controls.
The study wasn't measuring whether vaccination prevented shingles outbreaks. It was asking a more fundamental question: does vaccination against the herpes zoster virus change how fast people age at the biological level?
The answer was yes — across five independent aging measures, all of them statistically significant.
| Aging Measure | Direction | p-value |
| Epigenetic aging (DunedinPACE) | Slower | p = 0.0001 |
| Transcriptomic aging | Slower | p < 0.0001 |
| Composite biological aging score | Lower | p = 0.0002 |
| Inflammation markers | Lower | p = 0.003 |
| Adaptive/innate immunity & cardiovascular hemodynamics | Improved | Multiple significant |
The effects weren't transient. When the researchers examined how long benefits persisted, they found that the association with slower biological aging held for more than four years after vaccination. This is not a short-lived immune boost — it appears to represent a sustained shift in the pace of aging.
The analysis adjusted for sociodemographic factors, health behaviors, pre-existing conditions, and other covariates. The effect survived those adjustments.
Citation: Kim & Crimmins. "Association between shingles vaccination and slower biological aging: Evidence from a US population-based cohort study." *GeroScience*, 2025. PMID: 41556115.
To understand why suppressing herpes zoster would slow biological aging, you need to understand the virus's lifecycle.
Varicella-zoster virus (VZV) causes chickenpox on first exposure, typically in childhood. After that infection resolves, the virus does not leave your body. It retreats into the dorsal root ganglia — clusters of sensory neurons along your spine — and enters a state of latency. It hides there, silently, for decades.
This would be unremarkable if it stayed dormant forever. The problem is that it doesn't.
As the immune system ages — a process called immunosenescence — VZV begins to reactivate. Usually this produces the painful blistering rash we recognize as shingles. But the reactivation may not always be symptomatic. Subclinical reactivation — where the virus stirs without causing obvious disease — may be happening chronically in many older adults. And each reactivation event triggers an immune response.
The chronic inflammation hypothesis goes like this:
By vaccinating against VZV, you suppress this reactivation. Remove the hidden accelerant, and the aging machinery may run more slowly.
This is why the effect shows up across so many different aging measures simultaneously. It's not that the vaccine is directly modifying any one aging pathway — it's removing a chronic inflammatory input that was feeding multiple pathways at once.
The study used a particularly sophisticated battery of biological aging assessments. Understanding what each measure captures helps explain why results across all of them matter.
DunedinPACE is a DNA methylation-based measure of the *pace* of aging — how fast biological age is advancing per calendar year. Unlike older epigenetic clocks (Horvath, Hannum) that estimate biological age at a point in time, DunedinPACE measures the rate of aging. A score of 1.0 means aging at the population average pace; 0.8 means aging 20% slower than average; 1.2 means 20% faster.
DunedinPACE was developed at Duke University using longitudinal data from the Dunedin Study (a birth cohort followed from age 3 to 45), which makes it especially sensitive to real-world aging dynamics. It is currently among the most validated epigenetic aging measures for predicting age-related disease onset.
In the Kim & Crimmins study, vaccination was associated with a significantly *slower* DunedinPACE (p = 0.0001). This means the vaccinated group was aging at a slower rate at the DNA methylation level — not just scoring better on a static measure.
Gene expression changes predictably with age across thousands of genes. Transcriptomic aging measures capture how much a person's gene expression profile resembles that of an older versus younger individual. The Kim & Crimmins result showed slower transcriptomic aging in vaccinated individuals at p < 0.0001 — the strongest statistical signal in the study.
This is biologically meaningful because transcriptomic aging reflects what cells are actually doing in real time: which genes are being expressed, which pathways are active. Slower transcriptomic aging suggests the vaccinated individuals' cellular machinery was operating more like that of younger people.
The composite score aggregates multiple biomarkers — including measures from metabolic, immune, cardiovascular, and inflammatory domains — into a single summary of biological age relative to chronological age. It tends to be more robust than any single measure because it captures breadth rather than depth. A lower composite score means a younger biological age across systems. Vaccination was associated with a lower composite score (p = 0.0002).
Chronic systemic inflammation — measured through markers like C-reactive protein, interleukin-6, and TNF-alpha — is one of the most established predictors of aging-related disease and mortality. The inflammaging framework, developed by Claudio Franceschi, holds that the chronic low-grade inflammatory state that accompanies aging is not just a symptom but a cause of accelerated tissue deterioration. Vaccination was associated with lower inflammation at p = 0.003.
The standard mental model of vaccination is: you get a shot, your immune system makes antibodies, and if the pathogen appears, those antibodies neutralize it. Protection = infection prevention.
This study suggests a different and more interesting possibility: some vaccines may work as longevity interventions by removing chronic viral inflammatory burden. The herpes zoster vaccine isn't just preventing shingles — it's suppressing a hidden driver of background inflammation that was quietly accelerating the aging process across multiple biological systems.
If this mechanism is correct, the implications extend beyond VZV. Several other latent viruses — Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex viruses — share a similar biology: they establish lifelong latency, reactivate with immunosenescence, and generate chronic immune activation. CMV in particular has been extensively studied as a driver of immune aging. Vaccines or therapeutics targeting these latent viruses could potentially produce similar longevity effects.
The shingles vaccine is the one where we now have population-level data. And the data are compelling.
The current shingles vaccine in the US and most high-income countries is Shingrix (recombinant zoster vaccine, RZV), a product of GSK. It replaced the older Zostavax vaccine, which was a live attenuated vaccine with significantly lower efficacy.
Shingrix uses a different approach: it delivers a recombinant VZV glycoprotein E antigen alongside a powerful adjuvant (AS01B) that amplifies the immune response. This design produces stronger, more durable immunity than Zostavax.
Efficacy data from the ZOE trials:
Compare this to Zostavax, which was approximately 51% effective and declined significantly with age. Shingrix has made its predecessor obsolete. If you received Zostavax more than a few years ago, the CDC recommends getting Shingrix.
Dosing: Two intramuscular doses, separated by 2–6 months. Both doses are required for full protection.
Side effects: Shingrix has a high rate of local and systemic reactions — arm soreness, fatigue, muscle aches, and headache are common in the first 1–3 days after each dose. These are expected immune activation responses and are generally short-lived. They are more pronounced after the second dose. About 1 in 6 recipients experience reactions intense enough to interfere with normal activities briefly. This is not a reason to avoid the vaccine — it is a consequence of its powerful adjuvant producing the strong immune response that makes it so effective.
United States: The CDC recommends Shingrix for all adults 50 and older, regardless of whether they have had shingles before, whether they received Zostavax previously, or whether they are unsure if they had chickenpox as a child. Adults who are immunocompromised or immunosuppressed (including those on immunosuppressive medications) should discuss timing with their physician — Shingrix is non-live and generally safe in immunocompromised individuals, though the immune response may be lower.
United Kingdom: The NHS offers Shingrix free to adults turning 65 and to adults aged 70–79 who haven't previously been vaccinated. Immunocompromised adults aged 18+ are eligible regardless of age.
The case for getting it at 50, not waiting: The Kim & Crimmins data is drawn from adults 70+, but the biological case for early vaccination is straightforward. VZV reactivation risk increases progressively with immunosenescence, which begins well before age 70. Vaccinating at 50 — when the immune response to the vaccine is strongest — provides the most durable protection and potentially suppresses subclinical reactivation during the decades when cumulative inflammatory damage is being laid down.
United States — Medicare:
Under the Inflation Reduction Act, Part D covers adult vaccines recommended by the Advisory Committee on Immunization Practices (ACIP) at $0 cost-sharing for Medicare beneficiaries as of January 1, 2023. Shingrix is an ACIP-recommended vaccine. This means Medicare Part D enrollees pay nothing for both doses.
United States — Private insurance:
The ACA requires most private health insurance plans to cover ACIP-recommended vaccines with no cost-sharing when administered in-network. Shingrix is covered at $0 copay under most ACA-compliant plans. Check with your insurer and ensure you receive the vaccine from an in-network provider.
United States — Uninsured:
Without insurance, the two-dose Shingrix series costs approximately $400–530 at retail pharmacy prices (roughly $200–265 per dose). Some pharmacy programs and discount cards (GoodRx, Mark Cuban's Cost Plus Drugs) may reduce this, though availability varies. For uninsured adults, the cost is the primary barrier — and it is real.
United Kingdom — NHS:
Free for eligible adults (age 65; ages 70–79; immunocompromised adults 18+). Available at GP surgeries and NHS pharmacies. Adults who miss the cohort years can discuss eligibility with their GP.
The longevity community spends considerable energy debating the marginal benefit of NMN vs NR, the optimal fasting window, or which senolytic to take quarterly. The shingles vaccine deserves a higher priority in that conversation than it currently receives.
Consider the comparison:
For any adult 50+ building a longevity protocol, Shingrix belongs on the list alongside the better-evidenced lifestyle and supplement interventions — not because it's glamorous, but because the evidence-to-effort ratio is unusually favorable.
It pairs logically with other anti-inflammaging interventions like omega-3 supplementation, time-restricted eating, and exercise, all of which reduce chronic systemic inflammation through different mechanisms.
The Kim & Crimmins study is observational, not a randomized controlled trial. Observational studies cannot establish causation with the same certainty as RCTs. Despite adjusting for covariates, residual confounding is possible — vaccinated individuals may differ from unvaccinated individuals in ways not fully captured by the covariates available in the Health and Retirement Study.
Healthy user bias is a perennial concern in vaccine observational research: people who get recommended vaccines may be more health-conscious in general, leading to better outcomes regardless of the vaccine's direct effect. The authors addressed this with covariate adjustment, but the issue cannot be fully eliminated without randomization.
The study population was adults 70+. Whether similar biological aging effects would be seen in adults who vaccinate at 50 or 60 — which is the better intervention window — is not directly established by this data.
A randomized controlled trial measuring biological aging endpoints after Shingrix vaccination would be the definitive test of this mechanism. Given the existing data, that trial would be straightforward to design and the hypothesis is strong enough to warrant it.
The Kim & Crimmins paper is one of a small but growing body of evidence that some infectious agents we have learned to live with are quietly taxing our biology. VZV is one of the most tractable: we have a highly effective vaccine, it's recommended for the relevant age group, and we now have population-level data suggesting it slows biological aging.
The mental model that will serve longevity researchers and the people following this field is this: chronic infectious burden is a modifiable aging driver. The shingles vaccine is one tool to address it. Future work on CMV, EBV, and other latent viruses may yield additional tools. But for now, the one we have works, is free or low-cost for most people, and has just been linked to meaningfully slower biological aging in a large, well-characterized cohort.
If you are 50 or older and haven't received Shingrix, the evidence now suggests that getting it is not just protecting you from a painful rash — it may be removing a hidden drag on how fast you age.